{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:37:55Z","timestamp":1793151475779,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.smim.2021.101520","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:20:00Z","timestamp":1637126400000},"page":"101520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis"],"prefix":"10.1016","volume":"58","author":[{"given":"Charlie","family":"Bridgewood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bragazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0005","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6093","key":"10.1016\/j.smim.2021.101520_bib0010","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1221064","article-title":"New paradigms in type 2 immunity","volume":"337","author":"Pulendran","year":"2012","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.it.2005.10.003","article-title":"Understanding the IL-23\u2013IL-17 immune pathway","volume":"27","author":"McKenzie","year":"2006","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin\u201023 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0045","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"7534","key":"10.1016\/j.smim.2021.101520_bib0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2014a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41423-018-0192-y","article-title":"Tissue-resident lymphocytes: from adaptive to innate immunity","volume":"16","author":"Sun","year":"2019","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0065","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2781","article-title":"\u03b3\u03b4 T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/eji.201847759","article-title":"Tissue\u2010resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL\u201017","volume":"49","author":"Sobkowiak","year":"2019","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms4770","article-title":"IL-27 and IL-12 oppose pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1","volume":"5","author":"Heinemann","year":"2014","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.smim.2021.101520_bib0080","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/eji.201040539","article-title":"IFN\u2010\u03b3 and IL\u201012 synergize to convert in vivo generated Th17 into Th1\/Th17 cells","volume":"40","author":"Lexberg","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0085","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1084\/jem.182.5.1527","article-title":"Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice","volume":"182","author":"Gavett","year":"1995","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4049\/jimmunol.155.1.111","article-title":"IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes","volume":"155","author":"Marshall","year":"1995","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0095","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.smim.2021.101520_bib0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17\u2013producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2021.101520_bib0105","doi-asserted-by":"crossref","first-page":"8700","DOI":"10.4049\/jimmunol.181.12.8700","article-title":"T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17","volume":"181","author":"Yang","year":"2008","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2021.101520_bib0110","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.4049\/jimmunol.0803821","article-title":"T-bet inhibits the in vivo differentiation of parasite-specific CD4+ Th17 cells in a T cell-intrinsic manner","volume":"182","author":"Guo","year":"2009","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/intimm\/dxm045","article-title":"IL-6\u2013gp130\u2013STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state","volume":"19","author":"Nishihara","year":"2007","journal-title":"Int. Immunol."},{"issue":"13","key":"10.1016\/j.smim.2021.101520_bib0120","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0125","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.4049\/jimmunol.180.6.3746","article-title":"Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-\u03b3 on STAT3 and Smads","volume":"180","author":"Tanaka","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2567.2009.03189.x","article-title":"Plasticity of T\u2010cell phenotype and function: the T helper type 17 example","volume":"129","author":"Peck","year":"2010","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0135","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4049\/jimmunol.1600737","article-title":"Ex-Th17 (nonclassical Th1) cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells","volume":"198","author":"Basdeo","year":"2017","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0140","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.4049\/jimmunol.181.9.5842","article-title":"Cutting edge: IFN-\u03b3 enables APC to promote memory Th17 and abate Th1 cell development","volume":"181","author":"Kryczek","year":"2008","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2021.101520_bib0145","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-\u03b2 and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell\u2013mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0150","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.181.7.4733","article-title":"Induction of IL-17+ T cell trafficking and development by IFN-\u03b3: mechanism and pathological relevance in psoriasis","volume":"181","author":"Kryczek","year":"2008","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0155","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1002\/eji.200737840","article-title":"Enforced expression of GATA3 allows differentiation of IL\u201017\u2010producing cells, but constrains Th17\u2010mediated pathology","volume":"38","author":"van Hamburg","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0160","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/art.24329","article-title":"GATA\u20103 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis","volume":"60","author":"van Hamburg","year":"2009","journal-title":"Arthrit. Rheumat."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.05.038","article-title":"Increased frequency of dual-positive TH2\/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma","volume":"134","author":"Irvin","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0170","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1513\/pats.200808-087RM","article-title":"Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies","volume":"6","author":"Fahy","year":"2009","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1067\/mai.2001.117929","article-title":"IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines","volume":"108","author":"Molet","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0180","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.4049\/jimmunol.181.9.6117","article-title":"IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma","volume":"181","author":"Song","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0185","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2020.04.055","article-title":"Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis","volume":"147","author":"Ungar","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2021.101520_bib0190","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti\u2013IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am. J. Respir. Critical Care Med."},{"issue":"14","key":"10.1016\/j.smim.2021.101520_bib0195","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra1011040","article-title":"Filaggrin mutations associated with skin and allergic diseases","volume":"365","author":"Irvine","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.smim.2021.101520_bib0200","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"MHC-I-opathy'\u2014unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat. Rev. Rheum."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0205","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.smim.2021.101520_bib0210","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/ng.2438","article-title":"Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population","volume":"44","author":"Hirota","year":"2012","journal-title":"Nat. Genetics"},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Human Genetics"},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0220","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-\u03baB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat. genetics"},{"key":"10.1016\/j.smim.2021.101520_bib0225","series-title":"Seminars in Immunopathology","article-title":"Fine tuning","author":"Russell","year":"2021"},{"key":"10.1016\/j.smim.2021.101520_bib0230","doi-asserted-by":"crossref","unstructured":"El-Zayadi, A.A., et al., Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. 2017. 56(3): p. 488-493.","DOI":"10.1093\/rheumatology\/kew384"},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0235","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.smim.2021.101520_bib0240","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2021.101520_bib0245","series-title":"De Novo Psoriasis in Atopic Dermatitis Patients Treated With Dupilumab: A Retrospective Cohort","author":"Jaulent","year":"2020"},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0250","first-page":"1","article-title":"Enthesitis: much more than focal insertion point inflammation","volume":"20","author":"Watad","year":"2018","journal-title":"Curr. Rheum. Reports"},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0255","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","article-title":"Brief report: group 3 innate lymphoid cells in human enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0260","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/BOR.0000000000000529","article-title":"Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics","volume":"30","author":"Bridgewood","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"issue":"12","key":"10.1016\/j.smim.2021.101520_bib0265","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"\u2019MHC-I-opathy\u2019\u2014unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.smim.2021.101520_bib0270","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review","author":"Al\u2010Janabi","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"K\u00f6rber","year":"2018","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0280","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J. Dermatol. Sci."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0285","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52\u2010week, open\u2010label, phase 3 study (UNCOVER\u2010J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0290","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0295","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/intimm\/dxr006","article-title":"Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation","volume":"23","author":"Louten","year":"2011","journal-title":"Int. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0300","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2009.02.026","article-title":"IL-33\u2013activated dendritic cells induce an atypical TH2-type response","volume":"123","author":"Rank","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.smim.2021.101520_bib0305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cyto.2019.02.019","article-title":"IL-33 contributes to disease severity in Psoriasis-like models of mouse","volume":"119","author":"Duan","year":"2019","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.smim.2021.101520_bib0310","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/exd.12027","article-title":"IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation","volume":"21","author":"Balato","year":"2012","journal-title":"Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0315","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/imm.13203","article-title":"Interleukin\u201033 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response","volume":"160","author":"Chen","year":"2020","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0320","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.4049\/jimmunol.155.6.3234","article-title":"Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils","volume":"155","author":"Nonaka","year":"1995","journal-title":"J. Immunol."},{"issue":"7280","key":"10.1016\/j.smim.2021.101520_bib0325","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature08636","article-title":"Innate production of TH 2 cytokines by adipose tissue-associated c-Kit+ Sca-1+ lymphoid cells","volume":"463","author":"Moro","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0330","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri2735","article-title":"How are T H 2-type immune responses initiated and amplified?","volume":"10","author":"Paul","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0335","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2006.06.004","article-title":"IL-4 induces IL-13\u2013independent allergic airway inflammation","volume":"118","author":"Perkins","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0340","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","article-title":"IL-13 effector functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0345","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ni.2182","article-title":"Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity","volume":"13","author":"Liang","year":"2012","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0350","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL\u20104 and IL\u201013 with dupilumab, an IL\u20104R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0355","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cyto.2015.05.018","article-title":"Strategies targeting the IL-4\/IL-13 axes in disease","volume":"75","author":"May","year":"2015","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0167-5699(94)90021-3","article-title":"Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells","volume":"15","author":"Zurawski","year":"1994","journal-title":"Immunol. Today"},{"key":"10.1016\/j.smim.2021.101520_bib0365","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0370","first-page":"2673","article-title":"The interleukin-13 receptor \u03b12 chain: an essential component for binding and internalization but not for interleukin-13\u2013induced signal transduction through the STAT6 pathway","volume":"97","author":"Kawakami","year":"2001","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0375","first-page":"1","article-title":"IL-13R\u03b12 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses","volume":"7","author":"Lee","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm1332","article-title":"IL-13 signaling through the IL-13\u03b1 2 receptor is involved in induction of TGF-\u03b2 1 production and fibrosis","volume":"12","author":"Fichtner-Feigl","year":"2006","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.smim.2021.101520_bib0385","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.3390\/ijms20133324","article-title":"Scratching counteracts IL-13 signaling by upregulating the decoy receptor IL-13R\u03b12 in keratinocytes","volume":"20","author":"Ulzii","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0390","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4049\/jimmunol.1301761","article-title":"Endogenously expressed IL-13R\u03b12 attenuates IL-13\u2013mediated responses but does not activate signaling in human lung fibroblasts","volume":"193","author":"Chandriani","year":"2014","journal-title":"J. Immunol."},{"issue":"26","key":"10.1016\/j.smim.2021.101520_bib0395","doi-asserted-by":"crossref","first-page":"24915","DOI":"10.1074\/jbc.M502571200","article-title":"Characterization of the interaction between interleukin-13 and interleukin-13 receptors","volume":"280","author":"Arima","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.smim.2021.101520_bib0400","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.4049\/jimmunol.0901028","article-title":"IL-13R\u03b12 membrane and soluble isoforms differ in humans and mice","volume":"183","author":"Chen","year":"2009","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0405","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/sj.jid.5700687","article-title":"Regulation of IL-13 receptors in human keratinocytes","volume":"127","author":"Purwar","year":"2007","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.05.019","article-title":"TNF-\u03b1\/IL-17 synergy inhibits IL-13 bioactivity via IL-13R\u03b12 induction","volume":"134","author":"Badalyan","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0415","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.smim.2021.101520_bib0420","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.4049\/jimmunol.169.10.5673","article-title":"Regulation of virus-induced IL-12 and IL-23 expression in human macrophages","volume":"169","author":"Pirhonen","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2021.101520_bib0425","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2018.00200","article-title":"IL-36\u03b3 is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis","volume":"9","author":"Bridgewood","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0430","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2021.101520_bib0435","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","author":"Bridegwood","year":"2020","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0440","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.4049\/jimmunol.158.6.2898","article-title":"IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production","volume":"158","author":"Muchamuel","year":"1997","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0445","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.4049\/jimmunol.162.9.5224","article-title":"IL-4 inhibits the production of TNF-\u03b1 and IL-12 by STAT6-dependent and-independent mechanisms","volume":"162","author":"Levings","year":"1999","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.11.036","article-title":"Mast cell\u2013derived IL-13 downregulates IL-12 production by skin dendritic cells to inhibit the TH1 cell response to cutaneous antigen exposure","volume":"147","author":"Leyva-Castillo","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.11.043","article-title":"Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production","volume":"127","author":"Newcomb","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0460","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06933-4","article-title":"Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis","volume":"9","author":"Cambr\u00e9","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2021.101520_bib0470","first-page":"1","article-title":"Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis","author":"Gracey","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0475","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti\u2010TNF alpha: 5\u2010year follow\u2010up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0480","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.crohns.2010.11.001","article-title":"Infliximab and adalimumab-induced psoriasis in Crohn\u2019s disease: a paradoxical side effect","volume":"5","author":"Iborra","year":"2011","journal-title":"J. Crohns Colitis"},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0485","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/MPG.0000000000002349","article-title":"Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease","volume":"69","author":"Courbette","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0490","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology"},{"issue":"Supplement_1","key":"10.1016\/j.smim.2021.101520_bib0495","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz203.829","article-title":"P701 New onset spondyloarthropathy in vedolizumab treated IBD patients","volume":"14","author":"Tetley","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"8","key":"10.1016\/j.smim.2021.101520_bib0500","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/02713683.2010.486520","article-title":"Anti-TNF-\u03b1 treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment","volume":"35","author":"Kakkassery","year":"2010","journal-title":"Curr. Eye Res."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0505","doi-asserted-by":"crossref","DOI":"10.1136\/bjo.87.7.925","article-title":"Does etanercept induce uveitis?","volume":"87","author":"Reddy","year":"2003","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0510","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA","volume":"61","author":"O\u2019Toole","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0515","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J. Dermatological Treat."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2008.10.031","article-title":"IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response","volume":"123","author":"Eyerich","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0525","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/ijms21041314","article-title":"The role of Th17-related cytokines in atopic dermatitis","volume":"21","author":"Sugaya","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0530","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-\u03b3 are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J. Mol. Med."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0535","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2004.07.007","article-title":"IL-22 increases the innate immunity of tissues","volume":"21","author":"Wolk","year":"2004","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0540","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0550","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0555","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.jid.5700085","article-title":"IL-13-stimulated human keratinocytes preferentially attract CD4+ CCR4+ T cells: possible role in atopic dermatitis","volume":"126","author":"Purwar","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0560","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1046\/j.1523-1747.2000.00115.x","article-title":"A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+ CCR4+ lymphocytes into lesional atopic dermatitis skin","volume":"115","author":"Vestergaard","year":"2000","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0565","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/eji.200636420","article-title":"IL\u201018 enhances IFN\u2010\u03b3\u2010induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes","volume":"37","author":"Kanda","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0570","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","article-title":"IFN-\u03b3-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking","volume":"168","author":"Dufour","year":"2002","journal-title":"J. Immunol."},{"issue":"13","key":"10.1016\/j.smim.2021.101520_bib0575","doi-asserted-by":"crossref","first-page":"E2748","DOI":"10.1073\/pnas.1620954114","article-title":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36\u03b3","volume":"114","author":"Ainscough","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0580","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jdermsci.2019.04.002","article-title":"Cyto\/chemokine profile of in vitro scratched keratinocyte model: implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon","volume":"94","author":"Furue","year":"2019","journal-title":"J. Dermatol. Sci."},{"issue":"11","key":"10.1016\/j.smim.2021.101520_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108515","article-title":"The proinflammatory cytokine IL-36\u03b3 is a global discriminator of harmless microbes and invasive pathogens within epithelial tissues","volume":"33","author":"Macleod","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2021.101520_bib0590","article-title":"Increased expression of interleukin\u201023A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment","author":"Napolitano","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.smim.2021.101520_bib0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2020.09.500","article-title":"De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort","author":"Jaulent","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.smim.2021.101520_bib0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.01.022","article-title":"Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis","author":"Bakker","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.smim.2021.101520_bib0605","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jid.2021.02.007","article-title":"Dupilumab: an opportunity to unravel in vivo actions of IL-4 and IL-13 in humans","volume":"141","author":"Roesner","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0610","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2020.05.037","article-title":"TH cell diversity and response to dupilumab in patients with atopic dermatitis","volume":"147","author":"Trichot","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0615","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nm804","article-title":"Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease","volume":"9","author":"Ghoreschi","year":"2003","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0620","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0190-9622(93)70026-P","article-title":"Recombinant interferon gamma therapy for atopic dermatitis","volume":"28","author":"Hanifin","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0625","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0625.2006.00431.x","article-title":"Prevention of psoriasis\u2010like lesions development in fsn\/fsn mice by helminth glycans","volume":"15","author":"Atochina","year":"2006","journal-title":"Exp. Dermatol."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0630","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11926-018-0751-3","article-title":"Enthesitis: much more than focal insertion point inflammation","volume":"20","author":"Watad","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"issue":"12","key":"10.1016\/j.smim.2021.101520_bib0635","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.smim.2021.101520_bib0640","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.22758","article-title":"The concept of a \u201csynovio\u2010entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0645","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.berh.2018.08.002","article-title":"Uveitis in the spondyloarthopathies","volume":"31","author":"Sharma","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.smim.2021.101520_bib0650","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin\u201023\u2013dependent \u03b3\/\u03b4 T cells produce interleukin\u201017 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.smim.2021.101520_bib0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.03.965","article-title":"Differential requirement for CCR6 in IL-23-mediated skin and joint inflammation","author":"Shi","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0660","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+ CD4\u2212 CD8\u2212 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0665","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.34423","article-title":"\u03b2-glucan triggers spondylarthritis and Crohn\u2019s disease\u2013like ileitis in SKG mice","volume":"64","author":"Ruutu","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0670","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13075-015-0725-z","article-title":"Investigation of the relationship between the onset of arthritis and uveitis in genetically predisposed SKG mice","volume":"17","author":"Lee","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0675","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.38638","article-title":"Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice","volume":"66","author":"Benham","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037995","article-title":"AAV2-mediated combined subretinal delivery of IFN-\u03b1 and IL-4 reduces the severity of experimental autoimmune uveoretinitis","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.smim.2021.101520_bib0685","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/bjo.82.10.1195","article-title":"Treatment of uveitis with recombinant human interleukin-13","volume":"82","author":"Roberge","year":"1998","journal-title":"Br. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.smim.2021.101520_bib0690","first-page":"2275","article-title":"Inhibition of endotoxin-induced uveitis and potentiation of local TNF-\u03b1 and interleukin-6 mRNA expression by interleukin-13","volume":"40","author":"Marie","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0695","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/annrheumdis-2011-200478","article-title":"Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails","volume":"71","author":"Ash","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101520_bib0700","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23","author":"McGonagle","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0705","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000343607","article-title":"Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy","volume":"225","author":"Aydin","year":"2012","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0710","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/rheumatology\/kel214","article-title":"The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis\u2014a high-resolution MRI and histological study","volume":"46","author":"Tan","year":"2006","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0715","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.smim.2021.101520_bib0720","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101520_bib0725","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217309","article-title":"Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression","author":"Watad","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.smim.2021.101520_bib0730","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1002\/art.24128","article-title":"Investigation of association of the IL12B and IL23R genes with psoriatic arthritis","volume":"58","author":"Filer","year":"2008","journal-title":"Arthritis Rheum.: Off. J. Am. Coll. Rheum."},{"issue":"7","key":"10.1016\/j.smim.2021.101520_bib0735","first-page":"1449","article-title":"Genetics of psoriasis and psoriatic arthritis: update and future direction","volume":"35","author":"Duffin","year":"2008","journal-title":"J. Rheum."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0740","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/ard.2010.143123","article-title":"Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0745","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2010.147421","article-title":"IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients","volume":"70","author":"Eder","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0750","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.gene.6364451","article-title":"Variants in the 5q31 cytokine gene cluster are associated with psoriasis","volume":"9","author":"Chang","year":"2008","journal-title":"Genes Immun."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0755","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0760","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2010.147421","article-title":"IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients","volume":"70","author":"Eder","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.smim.2021.101520_bib0765","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2021.101520_bib0770","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0775","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0780","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.smim.2021.101520_bib0785","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.smim.2021.101520_bib0790","article-title":"A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition","author":"McInnes","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0795","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.18730","article-title":"Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series","volume":"183","author":"de Wijs","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0800","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.smim.2021.101520_bib0805","article-title":"Increased expression of IL\u201023A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment","author":"Napolitano","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.smim.2021.101520_bib0810","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14169","article-title":"Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns","author":"D\u2019Ambra","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"6","key":"10.1016\/j.smim.2021.101520_bib0815","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/DER.0000000000000509","article-title":"Psoriasis-like dermatitis developing in a patient with atopic dermatitis treated with dupilumab","volume":"30","author":"Stout","year":"2019","journal-title":"Dermatitis"},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0820","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/DER.0000000000000481","article-title":"Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis","volume":"30","author":"Fowler","year":"2019","journal-title":"Dermatitis"},{"key":"10.1016\/j.smim.2021.101520_bib0825","series-title":"SAGE Open Medical Case Reports","article-title":"Psoriasis appearing after dupilumab therapy in atopic dermatitis: a case report","author":"Kim","year":"2020"},{"key":"10.1016\/j.smim.2021.101520_bib0830","doi-asserted-by":"crossref","DOI":"10.1111\/ced.14207","article-title":"Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab","author":"Ferrucci","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0835","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jdcr.2020.01.012","article-title":"Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis","volume":"6","author":"Varma","year":"2020","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.smim.2021.101520_bib0840","series-title":"Psoriasis in dupilumab-treated atopic dermatitis. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete","author":"Senner","year":"2020"},{"issue":"4","key":"10.1016\/j.smim.2021.101520_bib0845","article-title":"Clinical psoriasiform dermatitis following dupilumab use for autoeczematization secondary to chronic stasis dermatitis","volume":"12","author":"Schrom","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0850","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.alit.2020.02.004","article-title":"An asthmatic case of psoriasiform eruption caused by administration of dupilumab","volume":"69","author":"Matsuda","year":"2020","journal-title":"Allergol. Int."},{"key":"10.1016\/j.smim.2021.101520_bib0855","article-title":"Onychodystrophy associated with dupilumab therapy for atopic dermatitis","author":"Zubek","year":"2020","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.smim.2021.101520_bib0860","article-title":"A case-report of uveitis secondary to dupilumab treatment for atopic dermatitis","author":"Ayasse","year":"2020","journal-title":"JAAD Case Rep."},{"issue":"3","key":"10.1016\/j.smim.2021.101520_bib0865","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.smim.2021.101520_bib0870","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.smim.2021.101520_bib0875","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16239","article-title":"Polyenthesitis during treatment with dupilumab for atopic dermatitis","author":"Ishibashi","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.smim.2021.101520_bib0880","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.15872","article-title":"Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib","author":"Komaki","year":"2021","journal-title":"J. Dermatol."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532321000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532321000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:23:19Z","timestamp":1760916199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532321000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":176,"alternative-id":["S1044532321000518"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2021.101520","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2021.101520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101520"}}